As opposed to reduced TEX being beneficial in cancer, reduced TEX has been associated with disease progression and increased severity in some autoimmune diseases including systemic lupus erythematosus (SLE), antineutrophil cytoplasmic antibody-associated vasculitis, and type 1 diabetes (T1D) (8–11). This evidence concerns the gene TEX46 and type 1 diabetes mellitus.